Reprosent, a cancer care mobile application that allows patients to record their symptoms, has won the Astellas Oncology Changing Cancer Care Prize and will receive a $100,000 grant.
The Astellas Oncology Changing Cancer Care prize awards non-treatment companies that are working to improve cancer care. Reprosent allows patients to track their own symptoms in hopes of giving patients more control over their treatment and reducing clinician burnout, according to the Aug. 8 Astellas news release.
"Cancer patients need better inclusion in their care, and our app and reports inform clinical conversations to manage what is most important — the patient's lived experience," Reprosent founder and CEO Aimee DeGolyer said. "Patients or their caregivers can log symptoms in the app daily and provide the data to their healthcare providers to help them make more informed decisions tailored to the patient."